🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

203+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 203 recruiting trials for “combined-hepatocellular-carcinoma-and-cholangiocarcinoma

Phase 2RecruitingNCT05809869

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

👨‍⚕️ Victor Ho-Fun Lee, MD, The University of Hong Kong📍 1 site📅 Started Feb 2023View details ↗
NARecruitingNCT05957250

[68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer

👨‍⚕️ Rutger-Jan Swijnenburg, MD, PhD, Amsterdam UMC, location AMC📍 1 site📅 Started Feb 2023View details ↗
Phase 2RecruitingNCT05625893

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

👨‍⚕️ Jeong Il Yu, MD, PhD, Samsung Medical Center📍 1 site📅 Started Jan 2023View details ↗
Phase 3RecruitingNCT05489289

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

👨‍⚕️ Jia Fan, Ph.D., Fudan University📍 1 site📅 Started Jan 2023View details ↗
RecruitingNCT06806579

Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

👨‍⚕️ Francesco Tovoli, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 24 sites📅 Started Dec 2022View details ↗
Phase 1, PHASE2RecruitingNCT05652920

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

🏥 OriCell Therapeutics Co., Ltd.📍 7 sites📅 Started Dec 2022View details ↗
Phase 2RecruitingNCT05678270

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

👨‍⚕️ Jin Li, Shanghai East Hospital📍 44 sites📅 Started Nov 2022View details ↗
Phase 2, PHASE3RecruitingNCT05408221

the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma

👨‍⚕️ Cai Jian qiang, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 5 sites📅 Started Nov 2022View details ↗
Phase 3RecruitingNCT05608213

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

🏥 Second Affiliated Hospital of Guangzhou Medical University📍 1 site📅 Started Nov 2022View details ↗
NARecruitingNCT05718492

A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents

👨‍⚕️ Ming Zhao, M.D. & Ph.D., Sun Yat-sen University📍 1 site📅 Started Oct 2022View details ↗
Phase 1RecruitingNCT05285358

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

👨‍⚕️ Daneng Li, MD, City of Hope Medical Center📍 1 site📅 Started Sep 2022View details ↗
NARecruitingNCT05443087

TARGETed Therapy Drug MONITOring in DIGestive Oncology

👨‍⚕️ David MALKA, Dr, Gustave ROUSSY - VILLEJUIF📍 29 sites📅 Started Aug 2022View details ↗
Phase 1RecruitingNCT05096715

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

👨‍⚕️ Jennifer Y Wo, MD, Massachusetts General Hospital📍 3 sites📅 Started Aug 2022View details ↗
NARecruitingNCT05484908

Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

👨‍⚕️ Wenxiong Xu, Doctor, Third Affiliated Hospital, Sun Yat-Sen University📍 1 site📅 Started Aug 2022View details ↗
Phase 4RecruitingNCT05124002

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

👨‍⚕️ ZHANG YUEWEI, MD, Beijing Tsinghua Chang Gung Hospital📍 1 site📅 Started Aug 2022View details ↗
Phase 2Enrolling by InvitationNCT05171335

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

👨‍⚕️ Maen Abdelrahim, MD, The Methodist Hospital Research Institute📍 1 site📅 Started Jun 2022View details ↗
RecruitingNCT05534906

The Detection of Small Early Liver Cancer With Natural History Follow up

👨‍⚕️ Ellie Barnes, University of Oxford📍 1 site📅 Started May 2022View details ↗
NARecruitingNCT05053555

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

👨‍⚕️ Joshua Kuban, M.D. Anderson Cancer Center📍 1 site📅 Started Apr 2022View details ↗
Phase 2RecruitingNCT05304234

Liver Cancer Disparities in American Indian and Alaska Native Persons

👨‍⚕️ George Ioannou, MD, MS, University of Washington📍 1 site📅 Started Apr 2022View details ↗
NARecruitingNCT05203120

A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma

👨‍⚕️ Britta Weber, MD PhD, Danish Center of Particle Therapy📍 3 sites📅 Started Apr 2022View details ↗
← PreviousPage 8 of 11Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →